Victory Capital Management
CTKB icon

Victory Capital Management’s Cytek Biosciences CTKB Stock Holding History

Victory Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.5K Sell
13,655
-3,966
-23% -$16.9K ﹤0.01% 2376
2026
Q1 		$77K Sell
17,621
-7
-0% -$33 ﹤0.01% 2288
2025
Q4 		$89K Sell
17,628
-2,805
-14% -$13K ﹤0.01% 2281
2025
Q3 		$70.9K Sell
20,433
-852
-4% -$3.2K ﹤0.01% 2321
2025
Q2 		$72.4K Sell
21,285
-329
-2% -$1.1K ﹤0.01% 2357
2025
Q1 		$86.7K Sell
21,614
-439
-2% -$2.27K ﹤0.01% 2323
2024
Q4 		$143K Sell
22,053
-692
-3% -$4.12K ﹤0.01% 2289
2024
Q3 		$126K Sell
22,745
-255
-1% -$1.45K ﹤0.01% 2293
2024
Q2 		$128K Buy
23,000
+835
+4% +$5.01K ﹤0.01% 2265
2024
Q1 		$149K Buy
22,165
+607
+3% +$4.8K ﹤0.01% 2257
2023
Q4 		$197K Sell
21,558
-7,820
-27% -$49.2K ﹤0.01% 2239
2023
Q3 		$162K Sell
29,378
-3,497
-11% -$28.1K ﹤0.01% 2234
2023
Q2 		$281K Buy
32,875
+4,161
+14% +$37.3K ﹤0.01% 2130
2023
Q1 		$264K Buy
+28,714
New +$309K ﹤0.01% 2179
2022
Q3 		– Sell
-10,379
Closed -$111K – 2713
2022
Q2 		$111K Sell
10,379
-26
-0.2% -$259 ﹤0.01% 2451
2022
Q1 		$98K Sell
10,405
-295
-3% -$3.98K ﹤0.01% 2515
2021
Q4 		$175K Buy
+10,700
New +$224K ﹤0.01% 2507

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Victory Capital Management's CTKB Position: Q2 2026 in Review

Victory Capital Management reduced its Cytek Biosciences (CTKB) stake by 23% in Q2 2026, selling an estimated $16.9K and leaving 13,655 shares worth $60.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2376.

Victory Capital Management first reported a position in CTKB in Q4 2021 and has held it in 17 quarters since. The position peaked at $281K in Q2 2023. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Victory Capital Management held 13,655 shares of Cytek Biosciences worth $60.5K as of Q2 2026.
  • Victory Capital Management sold 3,966 Cytek Biosciences shares in Q2 2026, an estimated $16.9K.
  • Cytek Biosciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2376 holding.
  • Victory Capital Management first reported a position in Cytek Biosciences in Q4 2021 and has held it in 17 quarters since.
  • Victory Capital Management's Cytek Biosciences position peaked at $281K in Q2 2023.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.